HRSA

Meet RxStrategies in Philadelphia for 340B Summit

Jonathan Ghenn and Rhodie Smith will be attending and meeting with industry leaders during the 4th Annual Covered Entities 340B Summit hosted by World Congress, May 16 – 17 in Philadelphia, PA. RxStrategies is proud to be a Supporting Sponsor for the Summit. This event brings HRSA grantees and covered entities together to discuss the…

Read More...

Comprehensive Solutions for Your FQHC

According to NACHC, “community health centers serve as the primary medical home for more than 27 million people in 10,400 rural and urban communities across America.” Just one form of Federally Qualified Health Centers (FQHC), community health centers receive funds from the HRSA Health Center Program to support and serve underserved areas (HRSA). The number…

Read More...

October 2017 – 340B Insider

Welcome to the October edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.    340B INDUSTRY NEWS UPDATE: HOUSE ENERGY & COMMERCE OVERSIGHT SUBCOMMITTEE HEARING On October 11, the House Energy & Commerce (E&C) oversight subcommittee held a second hearing on the 340B program, focusing on how Covered…

Read More...

Clinical Insights: August 25, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Gocovri™ (amantadine) – August 24, 2017 – Adamas Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri™ (amantadine) extended release capsules…

Read More...

Clinical Insights: July 14, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval Blincyto® (blinatumomab) – New Expanded Indication Approval – July 11, 2017 – Amgen announced that the U.S. Food and Drug…

Read More...

Clinical Insights: June 30, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval No new updates.   New Drug Shortage June 21, 2017 Cromolyn Sodium Inhalation Solution, USP (Currently in Shortage) New…

Read More...

Clinical Insights: June 2, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Rebinyn® (Coagulation Factor IX (Recombinant), GlycoPEGylated) – May 31, 2017 – Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application…

Read More...

May 2017 – 340B Insider

Welcome to the May edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.    CELEBRATING 25 YEARS OF THE 340B PROGRAM RxStrategies Supports Conference as Pinnacle Leader Sponsor July 10 – 12 | Washington, D.C. This year marks 25 years with the 340B program in place! Along…

Read More...

NOVEMBER 2016 – 340B INSIDER

Welcome to the November edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. AFFORDABLE CARE ACT – WHAT IS ON THE HORIZON RxStrategies works closely with a number of industry thought leaders to keep a pulse on issues potentially impacting the 340B Drug Pricing Program. With…

Read More...

August 340B Insider

Welcome to the August edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   340B RECERTIFICATION REMINDER   Recertification Deadline September 9    340B Health sent a reminder to Covered Entities (CEs) regarding the Sept. 9 deadline to recertify information in the 340B program database. It is vital to…

Read More...

340B Orphan Drug Rule Invalidated

U.S. District Judge Rudolph Contreras has ruled that HRSA lacks regulatory authority to promulgate regulations expanding access to 340B discounts for so-called Orphan Drugs.   Rules that went into effect in October of 2013 implemented provisions of the Affordable Care Act that excluded orphan drugs from 340B pricing.  In the rules HRSA interpreted the exception…

Read More...

Family Planning Re-certification Webinar

RECERTIFICATION: FAMILY PLANNING (3/24/2014) The Office of Pharmacy Affairs (OPA) is required to recertify all participating 340b covered entities annually to ensure 340B database accuracy and promote compliance with 340B program requirements. OPA will hold an informational recertification webinar for Title X Family Planning Grantees on April 2nd, 2014, from 2-3 PM EDT. Conference Number:…

Read More...